Nicole Dale

About

Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.

Areas of Expertise

Published content

Read Good Laboratory Practice Always Sets the R&D Standard
- Preclinical Development
- Biomedical R&D
- Pharma Policy
- Drug Discovery
- pharma R&D
- Pharmaceutical R&D
- Translational & Pre-clinical Research
- Pharma Regulation
- Harmonisation Standards
- AI Drug Discovery
- AI Drug Development
- Computational Biology
- The Discovery Loop
- Data Integrity
- FDA
- Quality Assurance
- Pharmaceutical Compliance
- Laboratory Quality
- Regulatory Warning Letters
- Documentation
- Medical Writers
- Nonclinical Development
- Data Management
- Audit Findings
- ALCOA
Good Laboratory Practice Always Sets the R&D Standard
Read AlphaGenome Atlas: Mapping Every Possible DNA Variant
- AI Drug Discovery
- AI & Machine Learning
- Research Informatics
- Translational & Pre-clinical Research
- Preclinical Development
- AI Drug Development
- AI Pharma
- AI & Advanced Healthcare
- Rare Diseases
- Orphan Drugs
- Computational Biology
- Biomedical R&D
- Genetics & Molecular Biology
- Drug Discovery
- Tech and Innovation
- Biotech
- Machine Learning in Pharma
- LLMs in Pharma
- Multiomics
- Healthcare Technology
- Diagnostics
AlphaGenome Atlas: Mapping Every Possible DNA Variant
Read FDA Expedited IND Pilot Targets Faster First-In-Human Trials
- Regulatory Pathways
- Regulatory Strategy
- Clinical Trial Regulation
- Global Regulatory Affairs
- Regulatory Approvals
- Pharma Regulation
- FDA
- Drug Approval
- Preclinical Development
- clinical trials
- Clinical Trial Strategy
- Clinical Trial Design
- Medical Writers
- Clinical Research Organisations
- Study Protocol
- eTMF
- Pharma Policy
- Regulatory Submissions
- Ethics Review
- Oversight
- Orphan Drugs
- Rare Diseases
- Novel Therapeutics
FDA Expedited IND Pilot Targets Faster First-In-Human Trials
Read CDRH Rare Disease Impact Initiative Sets New FDA Focus
- Rare Diseases
- Medical Devices
- Pharma Policy
- Regulatory Pathways
- Regulatory & IP
- Pharma Regulation
- Regulatory Approvals
- Medtech
- patient stratification
- Patient Care
- Patient Centricity and Outcomes
- Global Regulatory Affairs
- Regulatory Strategy
- Clinical Data
- clinical trials
- Clinical Trial Strategy
- FDA
CDRH Rare Disease Impact Initiative Sets New FDA Focus